Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
04 août 2016 07h30 HE
|
Minerva Neurosciences, Inc.
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...
Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder
26 mai 2016 08h15 HE
|
Minerva Neurosciences, Inc
Reduction in depressive symptoms demonstrated Good tolerability and safety profile observed Positive effect on sleep architecture shown Differentiated mechanism of action WALTHAM,...